Xspray’s Hybrid Nilotinib Candidate XS003 Advances To FDA Review Stage

US Agency Sets June 2026 PDUFA Date For Reformulated Rival To Tasigna

 
• By Dean Rudge
  
Figure walking over blocks representing goals towards a flag finish
(Shutterstock)

More from Value Added Medicines

More from Products